 NEEDHAM, Mass., Oct. 04, 2021 GLOBE NEWSWIRE -- Candel Therapeutics, Inc. Nasdaq: CADL, a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that the Company will present novel biomarker data from the ongoing phase 1 clinical trial of CAN-3110 in recurrent high-grade glioma at the Society for Immunotherapy of Cancers SITC 36th Annual Meeting taking place November 10-14, 2021 in Washington D.C., and virtually. 